Hims & Hers Health, Inc. (HIMS)

Hims & Hers Health, Inc. runs a telehealth platform that connects patients with doctors over video, collects a prescription if one makes sense, and then delivers medication by mail. The company does not run hospitals or clinics. It does not employ the doctors—they are contractors. What it does is remove friction: patients can get help for common, well-understood conditions (erectile dysfunction, hair loss, weight loss, depression, anxiety, birth control, skin problems) without an appointment, a commute, or sitting in a waiting room. The doctor reviews a questionnaire, meets the patient on video for fifteen to thirty minutes, and either prescribes a medication or recommends other steps. The company fills the prescription and ships it out. Hims makes money from the telehealth visit fee and a margin on the medication markup. For a subset of conditions—mainly weight loss and certain mental health treatments—it also charges a monthly membership that includes regular check-ins and refill management.

Why telehealth matters, and why Hims picked the business it did

Getting a prescription has traditionally meant finding a doctor, booking an appointment weeks in advance, traveling to their office, waiting, and then going to a pharmacy. For common problems where the treatment is straightforward—you probably know whether you want to try medication for erectile dysfunction or hair loss—that process feels wasteful. The doctor is not going to discover anything surprising during an in-person visit; they are going to ask some questions, maybe examine you, maybe ask you to come back for a lab test, and either prescribe something familiar or refer you to a specialist.

Telehealth removes the travel and waiting. But the reason Hims has succeeded where many other telehealth startups crashed is that it picked conditions where that is actually the right business model. These are treatments where:

• The diagnosis is straightforward and does not require hands-on examination or complex testing.
• The medication is safe, FDA-approved, and well-understood.
• The patient often knows they want it before they call the doctor.
• The patient will happily fill the prescription repeatedly if it works.

Erectile dysfunction, hair loss (topical minoxidil and oral finasteride), and weight loss (injectable GLP-1 agonists) fit that profile perfectly. So does birth control, acne treatment, and simple anxiety or depression management for patients who have already tried therapy or know medication is right for them. These are not rare diseases that need specialist diagnosis. They are common, millions of people deal with them, and the treatment options are limited and well-known. That makes them ideal for a mail-order telehealth model.

How Hims actually gets paid

Hims generates revenue through four mechanisms. First, patients pay for a virtual visit—typically $75 to $120 depending on the condition. Not every visit results in a prescription (the doctor might recommend lifestyle changes, or find that medication is not right), but most do. The visit fee is the entry point.

Second, once a prescription is filled, Hims marks up the cost of the medication. A three-month supply of finasteride for hair loss, or a month of birth control, carries a margin that varies by condition and supply. These markups are substantial—often 100 to 300 percent of the cost to acquire the drug—which makes the medication margin the most profitable part of the business.

Third, Hims has introduced membership plans, particularly for weight loss (where patients on GLP-1 drugs like semaglutide or tirzepatide need ongoing monitoring and refills) and mental health (where monthly check-ins are clinically valuable). These memberships—typically $75 to $199 per month—are recurring revenue. A patient on a weight-loss program who checks in monthly and refills their injections every month becomes a high-LTV (lifetime value) customer.

Fourth, Hims generates a small amount of revenue from partnerships with employers and health plans, who integrate Hims telehealth into their benefit offerings to reduce their own medical costs.

The unit economics are favorable for weight loss and high-touch mental health conditions, where the customer stays on the platform for months or years and generates multiple visits and prescription refills. The unit economics are weaker for one-off visits (someone who buys a single prescription for dermatology and never comes back), but those one-off visits are still profitable if margin is calculated across the whole customer base.

Competition and the weight-loss boom

For years, Hims’ main competitive threat came from other direct-to-consumer telehealth companies—Amazon’s Clinic+ and other smaller players—and from established players like Teladoc that connected patients with doctors for more serious conditions. But the introduction of GLP-1 agonist drugs (semaglutide, tirzepatide) for weight loss has created a massive new market. These drugs work, they are in shortage, and they are expensive. Patients who want them are willing to pay for telehealth visits to get them, and they are willing to come back monthly for refills and check-ins.

Hims recognized this opportunity early and made weight loss a strategic focus, building membership programs and supply chains around it. But the weight-loss market has attracted mainstream competition: traditional pharmacies like CVS and Walgreens now offer telehealth weight-loss programs. Obesity clinics and primary-care physicians are offering GLP-1 drugs directly. Insurance companies are beginning to cover these medications. That means Hims no longer has a monopoly on convenient access to weight-loss drugs, but it remains one of the largest direct-to-consumer providers with a streamlined process and a recognizable brand.

Challenges and risks

Hims operates in a regulatory environment that is both an opportunity and a constraint. Telehealth requires state medical boards to have licensed doctors on staff or under contract in every state. That makes the company vulnerable to changes in telehealth regulation—if states become stricter about who can prescribe via video, or if they require in-person initial visits, Hims’ model becomes harder to scale. Conversely, if states continue to loosen telehealth rules, the company benefits.

The drug supply chain is another vulnerability. When semaglutide shortages occur (as they have in recent years), Hims’ ability to fulfill patient orders suffers, and customers may seek out competitors or abandon the service. The company has limited control over drug supply, which sits upstream with manufacturers.

Reimbursement is a wild card. Today, Hims operates primarily as a cash-pay service—patients pay out of pocket for the visit and the medication. But if more insurance plans begin covering telehealth visits for these conditions (or if Medicare expands coverage), the business model shifts. Insurance coverage could drive volume but compress margins, since insurance reimbursement for a telehealth visit is typically lower than what cash-pay patients will pay.

Finally, there is the question of whether telehealth for simple conditions remains a durable business long-term. If weight loss becomes a mainstream part of primary care, and if primary-care doctors can prescribe GLP-1 drugs as easily as Hims can, Hims loses its convenience advantage. The company’s response has been to emphasize the speed, ease, and brand recognition of its platform over generic direct-to-consumer telehealth.

How to research Hims as an investment

Start with the company’s annual 10-K (SEC CIK 0001773751) and quarterly earnings releases. Pay attention to the number of active patients, the repeat rate (what percentage of patients return for another visit or refill within a year), and the average revenue per patient across the full customer lifetime. These metrics reveal whether customers are sticky or whether the business depends on constantly acquiring new one-off visitors.

Track gross margins and customer acquisition costs. Hims spends on marketing and digital advertising to drive new patient sign-ups; if that spending is efficient relative to the lifetime value of a customer, the business scales. If acquisition costs are rising faster than customer value, it is a warning sign.

Watch developments in drug supply (particularly for GLP-1 agonists, which are the company’s growth driver) and insurance reimbursement for telehealth. Both could shift the business materially. Finally, keep an eye on competition from traditional pharmacies and from primary care. The core question for investors is whether Hims has built a defensible brand and customer habit around convenience, or whether telehealth is a commodity service that any pharmacy or doctor can offer at lower cost.